Alterity Therapeutics to Present at the MST Access 'Hidden Gems in Life Sciences' Webinar

Company Overview - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases [2] - The company's lead asset, ATH434, is being evaluated in two Phase 2 clinical trials for Multiple System Atrophy, targeting various Parkinsonian disorders [2] Webinar Announcement - David Stamler, M.D., CEO of Alterity, will present a company overview at the MST Access 'Hidden Gems in Life Sciences' webinar on June 13, 2024, in Australia and June 12, 2024, in the United States [1] - The webinar will allow investors to ask questions at the conclusion of the presentation, and a recording will be available on the company's website afterward [2] Contact Information - Investor and media contacts are provided for both Australia and the U.S. to facilitate further inquiries [3]